Knowledge Library
EML4-ALK Cell Lines and In Vivo Models
The EML4-ALK fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs), making this oncogene an important drug target. The development of ALK tyrosine kinase inhibitors (ALK-TKIs) has been a major advance in treating NSCLC with this fusion gene, but acquired resistance to ALK-TKIs ultimately limits their use. To support the development of next-generation …Read More >
OncoWuXi Express: FaDu ATM Knockout Tumor model
OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our FaDu ATM KO tumor model. Introduction: As reported, several physiological processes, such as the production of reactive oxygen species during …Read More >
Immune-Avatar Humanized Tumor Models
To support antitumor efficacy testing and address the challenges of clinical translatability, WuXi AppTec offers extensive panels of immune-avatar humanized mouse models. Our platform includes hPBMC, hHSC, and hNK humanized models with enabling studies from our platform of over 1,700 CDX and PDX models. These well-established models cover multiple cancer types, including breast, lung, liver, …Read More >
Expanded Applications of PDX Models
Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >
Leveraging Animal Models to Combat Drug Resistance in Cancer Therapy
Cancer, globally recognized as a significant threat to public health, can be effectively controlled in its early stages through chemotherapy, targeted therapy, and immunotherapy, all of which inhibit tumor growth. However, an inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. Unraveling the underlying mechanisms of resistance is pivotal in overcoming …Read More >
Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics
SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >
Colitis-Associated Cancer Mouse Model
The cumulative impact of chronic inflammation in patients with inflammatory bowel disease (IBD) predisposes them to the development of IBD-associated colorectal cancer. To support drug discovery research in this area, WuXi AppTec has developed a colitis-associated cancer mouse model to reflect the human colon’s carcinogenesis pattern derived from inflammation. Key features of this model include …Read More >
Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment
SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by upregulating PD-L1 expression. Consequently, combining KRAS G12C inhibitors with immune checkpoint blockers shows promising benefits. To better understand the mechanisms underlying the combined inhibition of KRAS G12C inhibitor AMG 510, and anti-PD-1 antibody nivolumab, LU-01-0361 …Read More >
Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
DNA-dependent protein kinase (DNA-PK) plays an important role in the overall survival and proliferation of cells, making this enzyme an intriguing target for the treatment of a variety of cancers. In our latest publication, WuXi AppTec scientists contributed to the discovery and characterization of ZL-2201, a potent and highly selective small molecule DNA-PK inhibitor. In …Read More >